Minerva Neurosciences (NERV) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Minerva Neurosciences (NERV) over the past year, gaining 3.0% versus a loss of 49.2%. Over five years, NERV leads with a -76.4% price change compared with -92.5% for PDSB. Minerva Neurosciences is the larger company by market cap ($99.7 million vs $95.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | PDSB |
|---|---|---|
| Share price | $2.00 | $0.7774 |
| Market cap | $99.67M | $95.39M |
| 1-day change | -5.66% | -3.70% |
| YTD return | -50.25% | +0.96% |
| 1-year return | -49.24% | +2.97% |
| 5-year return | -76.42% | -92.46% |
| EPS (TTM) | $-33.83 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-293.42M | $-34.50M |
| 52-week high | $8.80 | $1.79 |
| 52-week low | $1.96 | $0.195 |
| Distance from 52-week high | -77.27% | -56.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +416.50% | +478.85% |
| Average volume | 164.71K | 25.64M |
| Shares outstanding | 49.84M | 122.70M |
| Employees | 7 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed NERV by 52.2 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NERV vs PDSB FAQ
Which is bigger, Minerva Neurosciences or PDS Biotechnology?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $99.67M compared with $95.39M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, NERV or PDSB?
PDSB returned +2.97% over the past 12 months, compared with -49.24% for NERV (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.